Sign in to view content

Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER

David A. Eichenbaum, MD, FASRS

Video
Published 2021

Related

Brolucizumab: Will it Make a Differance
Andrew P. Schachat, MD
Updates from the Field
2018
A Comparison of the Anatomical Efficacy of Brolucizumab Versus Aflibercept in nAMD Patients: Matched 16-Week Results From the HAWK and HARRIER Studies
Pravin U. Dugel, MD
Annual Meeting Talks
2018
Association Between Early Vision-Related Quality of Life (QoL) Outcomes and Anatomic Dryness in neovascular AMD and DME in the VIEW and FAME trials
Michael A. Singer, MD
On Demand Cases, Courses, and Papers
2019

Category: AMD-Neovascular

See more